Molecular Historical Income Statement
| MTEM Stock | USD 0.37 0.03 7.50% |
Historical analysis of Molecular Templates income statement accounts such as Research Development of 37.1 M can show how well Molecular Templates performed in making a profits. Evaluating Molecular Templates income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Molecular Templates's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Molecular Templates latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Molecular Templates is a good buy for the upcoming year.
Molecular |
About Molecular Income Statement Analysis
Molecular Templates Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Molecular Templates shareholders. The income statement also shows Molecular investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Molecular Templates Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Molecular Templates. It is also known as Molecular Templates overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Molecular Templates' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Molecular Templates current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Templates. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.At this time, Molecular Templates' Depreciation And Amortization is very stable compared to the past year. As of the 29th of November 2024, Interest Expense is likely to grow to about 2.8 M, while Operating Income is likely to drop (11 M).
Molecular Templates income statement Correlations
Click cells to compare fundamentals
Molecular Templates Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Molecular Templates income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 24.4M | 3.9M | 6.6M | 7.8M | 6.9M | 7.3M | |
| Interest Expense | 1.3M | 1.7M | 3.4M | 4.8M | 2.7M | 2.8M | |
| Other Operating Expenses | 67.8M | 119.7M | 118.8M | 108.6M | 67.8M | 49.9M | |
| Operating Income | (70.4M) | (100.8M) | (80.1M) | (88.9M) | (10.5M) | (11.0M) | |
| Ebit | (70.4M) | 106.6M | (80.1M) | (87.9M) | (5.5M) | (5.8M) | |
| Research Development | 50.5M | 93.0M | 84.7M | 82.4M | 48.9M | 37.1M | |
| Ebitda | (46.0M) | 110.5M | (73.4M) | (80.1M) | 1.4M | 1.5M | |
| Total Operating Expenses | 67.8M | 119.7M | 118.8M | 108.6M | 63.1M | 47.3M | |
| Net Income | (69.5M) | 104.9M | (79.3M) | (92.7M) | (8.1M) | (8.5M) | |
| Income Tax Expense | 116K | 5K | (3.7M) | 53K | (11K) | (10.5K) | |
| Selling General Administrative | 20.1M | 26.7M | 34.1M | 26.2M | 18.9M | 14.4M | |
| Income Before Tax | (69.4M) | 104.9M | (83.0M) | (92.7M) | (8.1M) | (8.5M) | |
| Total Other Income Expense Net | 1.0M | 205.8M | (2.9M) | (3.8M) | 2.3M | 2.2M | |
| Total Revenue | 19.5M | 18.8M | 38.7M | 19.8M | 57.3M | 60.2M | |
| Gross Profit | (31.0M) | 18.8M | 38.7M | 12.0M | 50.4M | 52.9M | |
| Net Income From Continuing Ops | (69.4M) | (104.9M) | (83.0M) | (92.7M) | (26.2M) | (27.5M) | |
| Cost Of Revenue | 50.5M | 93.0M | 6.7M | 7.8M | 6.9M | 6.6M | |
| Non Operating Income Net Other | (4.5M) | 951K | 3K | (3.4M) | (3.9M) | (4.1M) | |
| Net Income Applicable To Common Shares | (69.4M) | (104.9M) | (83.0M) | (92.7M) | (83.4M) | (79.3M) | |
| Interest Income | 2.3M | 1.0M | 434K | 988K | 1.5M | 892.5K | |
| Net Interest Income | 1.0M | (677K) | (2.9M) | (3.8M) | (2.6M) | (2.4M) | |
| Reconciled Depreciation | 1.2M | 3.9M | 6.6M | 7.4M | 7.3M | 4.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Templates. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Templates. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Templates listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.97) | Earnings Share (3.05) | Revenue Per Share 4.544 | Quarterly Revenue Growth (0.92) | Return On Assets (0.38) |
The market value of Molecular Templates is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Templates' value that differs from its market value or its book value, called intrinsic value, which is Molecular Templates' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Templates' market value can be influenced by many factors that don't directly affect Molecular Templates' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Templates' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Templates is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Templates' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.